Sugar Maple Asset Management’s Aquestive Therapeutics AQST Stock Holding History

Sugar Maple Asset Management’s Portfolio AQST Stock Details AQST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$542K	Buy	117,060 +34,000	+41%	+$151K	0.31%	58
2026 Q2	$346K	Buy	83,060 +25,000	+43%	+$105K	0.22%	69
2026 Q1	$241K	Buy	58,060 +3,210	+6%	+$13K	0.15%	77
2025 Q4	$354K	Buy	54,850 +42,850	+357%	+$267K	0.24%	62
2025 Q3	$67.1K	Hold	12,000	–	–	0.05%	79
2025 Q2	$39.7K	Sell	12,000 -17,500	-59%	-$50.2K	0.03%	74
2025 Q1	$85.6K	Buy	+29,500	New	+$89.3K	0.07%	64

Other funds holding AQST

BCM

Bratton Capital Management Fort Worth, Texas $45.4M AUM 17.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Simplify Asset Management Las Vegas, Nevada $6.11B AUM 3.71% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Sugar Maple Asset Management's AQST Position: Q3 2026 in Review

Sugar Maple Asset Management increased its Aquestive Therapeutics (AQST) stake by 41% in Q3 2026, buying an estimated $151K and bringing the position to 117,060 shares worth $542K. The position accounts for 0.31% of the portfolio, ranked #58.

Sugar Maple Asset Management first reported a position in AQST in Q1 2025 and has held it in 7 quarters since. 87 funds tracked by Wall St. Rank hold AQST as of Q3 2026.

Sugar Maple Asset Management held 117,060 shares of Aquestive Therapeutics worth $542K as of Q3 2026.
Sugar Maple Asset Management bought 34,000 Aquestive Therapeutics shares in Q3 2026, an estimated $151K.
Aquestive Therapeutics made up 0.31% of Sugar Maple Asset Management's portfolio in Q3 2026, its #58 holding.
Sugar Maple Asset Management first reported a position in Aquestive Therapeutics in Q1 2025 and has held it in 7 quarters since.
87 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.

Based on Sugar Maple Asset Management's 13F filing for Q3 2026, filed 13 Oct 2026.